SCHEMBL12448366

SCHEMBL12448366

COc1ccc([N+](=O)[O-])cc1OCCCN1CCOCC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.60
CYP2D6 P10635 4/20 0.59
CYP1A2 P05177 2/20 0.59
CYP2C19 P33261 2/20 0.59
SMN1; SMN2 Q16637 3/20 0.58
KDM4E B2RXH2 2/20 0.58
ALDH1A1 P00352 2/20 0.58
NPC1 O15118 2/20 0.58
RAB9A P51151 2/20 0.58
PKM P14618 2/20 0.56
MEN1 O00255 1/20 0.56
TSHR P16473 1/20 0.54
TDP1 Q9NUW8 1/20 0.53
KCNJ1 P48048 1/20 0.52
MAPT P10636 2/20 0.52
POLB P06746 1/20 0.52
DRD4 P21917 2/20 0.52
CYP2C9 P11712 2/20 0.50
CYP3A4 P08684 1/20 0.50
HPGD P15428 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31378679 0.95 KMT2A (0.60) KMT2ACYP2D6CYP1A2CYP2C19SMN1; SMN2
SCHEMBL1667288 0.95 KMT2A (0.60) KMT2ACYP2D6CYP1A2CYP2C19SMN1; SMN2
SCHEMBL3940129 0.94 KMT2A (0.61) KMT2ACYP2D6CYP1A2CYP2C19SMN1; SMN2
SCHEMBL4042588 0.92 KMT2A (0.59) KMT2ACYP2D6CYP1A2CYP2C19SMN1; SMN2
SCHEMBL2086647 0.89 KMT2A (0.61) KMT2ACYP2D6CYP1A2CYP2C19SMN1; SMN2
SCHEMBL18788160 0.89 HRH3 (0.56) CYP2D6CYP1A2CYP2C19SMN1; SMN2KDM4E
SCHEMBL5105861 0.88 ALDH1A1 (0.58) KMT2ACYP2D6CYP1A2CYP2C19SMN1; SMN2
SCHEMBL12448375 0.87 CYP1A2 (0.60) KMT2ACYP2D6CYP1A2CYP2C19SMN1; SMN2
SCHEMBL12448371 0.85 CYP1A2 (0.60) CYP2D6CYP1A2CYP2C19SMN1; SMN2KDM4E
SCHEMBL1928086 0.84 HRH3 (0.56) CYP2D6CYP1A2CYP2C19SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3442947-B1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS EPIZYME INC (US) 2023-06-07 EP disclosed
US-20210198277-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS Epizyme, Inc. 2021-07-01 US disclosed
EP-3442947-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS Epizyme Inc (US) 2019-02-20 EP disclosed
US-20170355712-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS Epizyme, Inc. 2017-12-14 US disclosed
US-20170355712-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS Epizyme, Inc. 2017-12-14 US disclosed
US-20170355712-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS Epizyme, Inc. 2017-12-14 US disclosed
WO-2017181177-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS Epizyme, Inc. (US) 2017-10-19 WO disclosed
WO-2017181177-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS Epizyme, Inc. (US) 2017-10-19 WO disclosed
US-20150352108-A1 AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON ALZHEIMER'S INSTITUTE OF AMERICA (US) 2015-12-10 US disclosed
US-20150352108-A1 AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON ALZHEIMER'S INSTITUTE OF AMERICA (US) 2015-12-10 US disclosed
US-20120238540-A1 AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 MYREXIS, INC. (US) 2012-09-20 US disclosed
US-20120238540-A1 AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 MYREXIS, INC. (US) 2012-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355712-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS SHMT1, BHMT, BHMT2 KMT2A 17/4885CYP2D6 671/4885CYP1A2 615/4885
US-20210198277-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS SHMT1, BHMT, BHMT2 KMT2A 17/4885CYP2D6 671/4885CYP1A2 615/4885
US-20150352108-A1 AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON TBK1, NFKBIA, CHUK KMT2A 3692/4885CYP2D6 4734/4885CYP1A2 4794/4885
US-20120238540-A1 AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 TBK1, NFKBIA, IKBKB KMT2A 1946/4885CYP2D6 4397/4885CYP1A2 4748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.